Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFZ52G)

• Drug Name: Anti-OX40 mab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMFZ52G

Molecule-Related Drug Atlas

Drug(s) Targeting OX40L receptor (CD134)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rocatinlimab	DMG1U5K	Atopic dermatitis	EA80	Phase 3	[3]
GBR 830	DM2VO9T	Atopic dermatitis	EA80	Phase 2	[4]
PF-04518600	DMZMUIL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
INCAGN01949	DMK7OHI	Advanced malignancy	2A00-2F9Z	Phase 2	[6]
INCAGN1949	DM7OE3X	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
TAK-252	DM1AKNI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
MEDI0562	DMYVBU6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
BGB-A445	DMQMEDH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
YH002	DMWVRHD	Aggressive cancer	2A00-2F9Z	Phase 1	[10]
YH006	DMRECC2	Aggressive cancer	2A00-2F9Z	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
OX40L receptor (CD134)	TTL31H0	TNR4_HUMAN	Modulator	[2]

References

• [1] OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013 Dec 15;73(24):7189-98.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1873).
• [3] An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023 Jan 21;401(10372):204-214.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Shattuck Labs.
• [9] Clinical pipeline report, company report or official report of BeiGene.
• [10] Clinical pipeline report, company report or official report of Biocytogen
• [11] Clinical pipeline report, company report or official report of Biocytogen